PIM1, a serine/threonine kinase, is known to be overexpressed predominantly in hematologic malignancies and is a downstream target of HOXA9, especially in AML with FLT3-ITD mutations (19, 42). This evidence concerns the gene MARK2 and hematologic disorder.